• Discovery

    Proprietary technologies used by our team include B cell Select, phage display, and single-step hybridoma cloning with semi-solid media and clone picking.
  • Alternative Species & Strains

    We have broad experience with transgenic animals, knock-out strains, and a variety of species including, but not limited to, chickens, rabbits, camelids, and more.
  • Targets

    Any target class including GPCRs, ion channels, phosphopeptides, small molecules, secreted proteins, etc. Antibodies generated for numerous applications, including therapeutic, immuno-onocology, CAR-T, and more.
  • Connect with Scientists

    Request a free target analysis with our experts.

ImmunoPrecise Featured Services

With over 25 years of experience in the custom antibody business, ImmunoPrecise provides high satisfaction through a customized professional approach.
B cell Select
B cell Select mAb Discovery

ImmunoPrecise is excited to offer custom B cell Select Antibody Discovery. This proprietary technology allows for selection of target specific B cells from any tissue in a variety of animal species.

Learn More: B cell Select

Phage Display
Phage Display

Our phage display approach is based on building custom immune libraries from multiple species, or the selection of antigen specific recombinant antibody fragments from our proprietary human or llama phage libraries.

Learn More: Phage Display

Hybridoma Development
Hybridoma Development

Coupled with advanced hybridoma technologies, Rapid Prime is ImmunoPrecise’s proprietary immunization protocol, which saves months in development time in combination with our Single-Step semi-solid media selection and clone picking. Positive hybridoma clones are identified just 32 days from project initiation.

Learn More: Hybridoma Development

Rabbit Monoclonals
Rabbit Monoclonals

ImmunoPrecise’s proprietary rabbit monoclonal development allows for the screening of the immune repertoire of the rabbit, creating the power to select the desired antibody directly from the B cells using our B cell Select antibody discovery platform.

Learn More: Rabbit mAbs

Antibody Optimization
Antibody Optimization

At ImmunoPrecise, we offer the following antibody optimization services: antibody chimerization, antibody humanization, and antibody affinity maturation.

Learn More: Antibody Optimization

Antibody Manufacturing
Antibody Manufacturing

Our proprietary expression technology is designed to deliver fast and large-scale production of (mammalian) recombinant proteins and antibodies for research and pre-clinical applications.

Learn More: Antibody Manufacturing

Start Your Project

We are ready to initiate the immunization phase of your custom antibody development project immediately.


ImmunoPrecise Conference and Tradeshows
  • ImmunoPrecise Exhibiting at Discovery on Target in Boston, MA, on September 16-19

    ImmunoPrecise Antibodies will participate in the 17th Annual Discovery on Target (DOT) being held Boston, MA September 16-19. With over 1,300 attendees and a variety of keynote speakers, training seminars, short courses, roundtables, and networking functions, DOT is said to be the industry’s preeminent event on novel drug target and technologies. Jennifer Bath, Ph.D., and

  • Shareholder Lab Visit: ImmunoPrecise Antibodies – Canada

    ImmunoPrecise Antibodies Ltd invites our shareholders to visit our Victoria Lab on Wednesday, August, 14th, followed by a social at Canoe Brewpub in Downtown Victoria. Shareholders will have the opportunity to tour our labs and meet with Dr. Jennifer Bath, President and CEO. We are confident that by seeing our company’s work in action, you

  • ImmunoPrecise Attending & Exhibiting at Antibody Engineering & Therapeutics Europe 2019

    The ImmunoPrecise Antibodies team will be exhibiting at Antibody Engineering & Therapeutics (AET) Europe 2019 in Amsterdam, NL from June 11th-13th, 2019. AET Europe is the industry’s European meeting for Antibody and Protein Therapeutic Science, Technology and Networking. This year’s conference will have a strong focus on “drug development” and will feature preclinical and clinical case